Ballentine Companions LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 54.1% within the third quarter, in line with its most up-to-date submitting with the SEC. The fund owned 1,529 shares of the biotechnology firm’s inventory after promoting 1,805 shares through the interval. Ballentine Companions LLC’s holdings in Biogen have been value $296,000 as of its most up-to-date SEC submitting.
Different hedge funds and different institutional traders have additionally modified their holdings of the corporate. Arlington Companions LLC boosted its holdings in shares of Biogen by 34.3% within the third quarter. Arlington Companions LLC now owns 19,214 shares of the biotechnology firm’s inventory valued at $3,724,000 after shopping for a further 4,902 shares through the interval. Duality Advisers LP acquired a brand new place in Biogen through the 1st quarter valued at about $1,290,000. Tocqueville Asset Administration L.P. boosted its stake in Biogen by 924.4% through the 1st quarter. Tocqueville Asset Administration L.P. now owns 46,200 shares of the biotechnology firm’s inventory valued at $9,962,000 after buying a further 41,690 shares through the interval. Sumitomo Mitsui Belief Holdings Inc. boosted its stake in Biogen by 0.9% through the 1st quarter. Sumitomo Mitsui Belief Holdings Inc. now owns 386,482 shares of the biotechnology firm’s inventory valued at $83,337,000 after buying a further 3,380 shares through the interval. Lastly, Cetera Funding Advisers boosted its stake in Biogen by 235.1% through the 1st quarter. Cetera Funding Advisers now owns 14,860 shares of the biotechnology firm’s inventory valued at $3,204,000 after buying a further 10,425 shares through the interval. 87.93% of the inventory is owned by institutional traders and hedge funds.
Insider Exercise
In different information, insider Priya Singhal bought 431 shares of the enterprise’s inventory in a transaction that occurred on Tuesday, September third. The shares have been bought at a median worth of $204.22, for a complete transaction of $88,018.82. Following the sale, the insider now owns 5,316 shares within the firm, valued at $1,085,633.52. The commerce was a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which will be accessed via the SEC web site. 0.16% of the inventory is owned by firm insiders.
Wall Road Analysts Forecast Progress
Various analysis analysts have issued experiences on BIIB shares. Royal Financial institution of Canada diminished their goal worth on shares of Biogen from $292.00 to $269.00 and set an “outperform” score for the corporate in a analysis word on Friday, October 4th. Wedbush diminished their goal worth on shares of Biogen from $210.00 to $205.00 and set a “impartial” score for the corporate in a analysis word on Monday, September twenty third. Raymond James reissued a “market carry out” score on shares of Biogen in a analysis word on Thursday, October tenth. Scotiabank diminished their goal worth on shares of Biogen from $275.00 to $244.00 and set a “sector outperform” score for the corporate in a analysis word on Friday, August 2nd. Lastly, Cantor Fitzgerald reissued an “obese” score and set a $292.00 goal worth on shares of Biogen in a analysis word on Monday, September ninth. 9 analysis analysts have rated the inventory with a maintain score, sixteen have given a purchase score and one has issued a robust purchase score to the corporate’s inventory. Primarily based on knowledge from MarketBeat.com, the corporate at the moment has a consensus score of “Reasonable Purchase” and a median goal worth of $271.39.
Learn Our Newest Analysis Report on BIIB
Biogen Inventory Up 1.8 %
NASDAQ BIIB opened at $185.01 on Tuesday. Biogen Inc. has a 12 month low of $181.24 and a 12 month excessive of $268.30. The corporate’s 50 day easy shifting common is $194.86 and its 200 day easy shifting common is $210.08. The corporate has a debt-to-equity ratio of 0.40, a present ratio of two.29 and a fast ratio of 1.48. The corporate has a market capitalization of $26.94 billion, a P/E ratio of 23.10, a PEG ratio of 1.87 and a beta of -0.06.
Biogen (NASDAQ:BIIB – Get Free Report) final launched its quarterly earnings outcomes on Thursday, August 1st. The biotechnology firm reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.00 by $1.28. Biogen had a internet margin of 11.98% and a return on fairness of 15.71%. The enterprise had income of $2.47 billion for the quarter, in comparison with analyst estimates of $2.39 billion. Throughout the identical quarter within the earlier 12 months, the enterprise earned $4.02 earnings per share. The agency’s income was up .4% in comparison with the identical quarter final 12 months. Equities analysis analysts count on that Biogen Inc. will put up 16.14 earnings per share for the present fiscal 12 months.
Biogen Firm Profile
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative ailments in the USA, Europe, Germany, Asia, and internationally. The corporate gives TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for a number of sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to deal with Alzheimer’s illness; FUMADERM to deal with plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
See Additionally
Obtain Information & Scores for Biogen Every day – Enter your electronic mail handle beneath to obtain a concise every day abstract of the most recent information and analysts’ rankings for Biogen and associated corporations with MarketBeat.com’s FREE every day electronic mail publication.
